Alabama and the University of Alabama Birmingham (UAB) are in the heart of a growing HIV/AIDS epidemic that disproportionately afflicts the most vulnerable populations The UAB Center for AIDS Research (CFAR) has been at the forefront of HIV prevention and therapeutic investigation for over 25 years. Seven years ago, the UAB CFAR formed the Alabama-Clinical Trials Unit (A-CTU): A partnership of UAB Investigators dedicated to conducting high-impact HIV-related studies in a resource poor region of the United States. The A-CTU has been conducting clinical studies sponsored by the HIV Vaccine Trials Network (HVTN), the Microbicide Trials Network (MTN), and the Adult Clinical Trials Group (ACTG) and shares resources In a single building The CTU has enrolled over 900 participants Into 45 separate clinical trials. This application provides plans to add the HIV Prevention Trials Network (HPTN) to create a single Clinical Research Site (CRS). This single, coordinated CTU addresses priority areas in HIV clinical research and utilizes established partnerships with the patient/participant community, experience In NIAID- and Industry-funded clinical trials, and collaborations with UAB CFAR investigators.
This application seeks approval to continue conducting clinical trials to advance our understanding of the treatment and prevention of HIV and related diseases. The Alabama Clinical Trials Unit plans to conduct these trials for several different NIH-sponsored networks Including the HVTN, HPTN, MTN, and ACTG at a the University of Alabama at Birmingham.
|Tassiopoulos, Katherine; Abdo, Mona; Wu, Kunling et al. (2017) Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS 31:2287-2294|
|Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69|
|Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111|
|Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60|
|Robbins, Gregory K; Cohn, Susan E; Harrison, Linda J et al. (2016) Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. HIV Clin Trials 17:165-72|
|Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995|
|Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7|
|Jacobson, Jeffrey M; Bosinger, Steven E; Kang, Minhee et al. (2016) The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Res Hum Retroviruses 32:636-47|
|Walsh, Stephen R; Moodie, Zoe; Fiore-Gartland, Andrew J et al. (2016) Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. J Infect Dis 213:541-50|
|Bar, Katharine J; Sneller, Michael C; Harrison, Linda J et al. (2016) Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 375:2037-2050|
Showing the most recent 10 out of 68 publications